| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2011-06-02 | Relovair® | chronic obstructive pulmonary disease (COPD) | 3 | GSK (UK) Theravance (USA) | Respiratory diseases |
| 2011-06-02 | Copaxone® (glatiramer acetate injection) | relapsing-remitting multiple sclerosis | 3 | Teva Pharmaceutical Industries (Israel) | Neurodegenerative diseases - Autoimmune diseases |
| 2011-05-31 | inecalcitol | castrate-resistant prostate cancer | 2a | Hybrigenics (France) | Cancer - Oncology |
| 2011-05-31 | back-up compound from its strategic alliance with Evotec | pain | 1 | Boehringer Ingelheim (Germany) | CNS diseases |
| 2011-05-31 | PredictMDx for Brain temozolomide | glioblastoma multiforme | 3 | MDxHealth (Belgium) | Cancer - Oncology |
| 2011-05-31 | CG-10639 (Granulocyte Colony Stimulating Factor (G-CSF) - formerly Neugranin) | breast cancer | 2 | Teva Pharmaceutical Industries (Israel) | Cancer - Oncology |
| 2011-05-26 | talactoferrin | non-small cell lung cancer | 2 | Agennix (Germany) | Cancer Oncology |
| 2011-05-25 | ACZ885 (canakinumab) | severe gouty arthritis |
3 | Novartis (Switzerland) | Inflammatory diseases |
| 2011-05-25 | rivaroxaban | prevention of recurrent strokes in patients with atrial fibrillation | 3 | Bayer (Germany) | Cardiovascular diseases - Cerebrovascular diseases |
| 2011-05-25 | influenza vaccine using Isconova’s adjuvant product Matrix M™ | seasonal influenza | 1 | Isconova (Sweden) | Infectious diseases |
| 2011-05-24 | SYN118 | Parkinson's disease |
2a | Biotie Therapies (Finland) | Neurodegenerative diseases - CNS diseases |
| 2011-05-23 | Ruconest® (Rhucin® in non-European territories - conestat alfa) | acute Hereditary Angioedema (HAE) attacks | 3 | Pharming (The Netherlands) | Rare diseases - Genetic diseases |
| 2011-05-23 | CRTH2 antagonist | seasonal allergic rhinitis |
2 | Actelion (Switzerland) | Allergic diseases - Immune diseases |
| 2011-05-19 | Nexavar® (sorafenib) | locally advanced or metastatic breast cancer previously treated with a bevacizumab containing regimen |
2b | Bayer (Germany) Onyx Pharmaceuticals (USA) | Cancer - Oncology |
| 2011-05-19 | ProstAtak®( aglatimagene besadenovec) | prostate cancer | 3 | Advantagene (USA - MA) | Cancer - Oncology |
| 2011-05-18 | EVT 101 | treatment-resistant depression | 2 | Evotec (Germany) Roche (Switzerland) | CNS diseases |
| 2011-05-18 | FSH-GEX® | in vitro fertilisation anovulatory infertility |
1 | Glycotope (Germany) | Gynecology - Women's health |
| 2011-05-17 | CT-011 | Diffuse Large B Cell Lymphoma | 2 | Teva Pharmaceutical Industries (Israel) CureTech (Israel) | Cancer - Oncology |
| 2011-05-16 | TB-403 (RG7334) | glioblastoma multiforme | 1b-2 | Roche (Switzerland) | Cancer - Oncology |
| 2011-05-16 | Lu AA21004 | major depressive disorder (MDD) | 3 | Lundbeck (Denmark) | Mental diseases - CNS diseases |
